Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* All patients 18 years and older who are already scheduled for primary total joint arthroplasty of the hip or knee~Exclusion Criteria for IV TXA administration~* Cardiac stent or ischemic stroke or coronary artery bypass graft (CABG)~* If patient is on anticoagulant, patient must have documented approval from a cardiologist that patient can be removed from anticoagulant for total joint arthroplasty procedure~* Renal impairment defined as serum Cr \> 1.5 or Cr Clearance \< 50 mL/min~* Severe ischemic heart disease~* Color blindness or problems with color vision~Criteria for Use of Topical TXA~* Topical TXA can be used in any patient meeting one of the exclusion criteria for IV TXA administration (Section 5.3b) as there is minimal systemic absorption with topical TXA~Absolute Exclusion Criteria~* History of deep vein thrombosis (DVT) or pulmonary embolism (PE)~* Known congenital thrombophilia~* History of thromboembolic or vascular disease~* Disseminated intravascular coagulation (DIC)~* History of seizures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous Tranexamic Acid (Type: EXPERIMENTAL): * 1g TXA administered intravenous piggyback at start of surgery OR~* 1g TXA administered intravenous piggyback at start and at time of closure of surgery
- Intravenous Placebo (Type: PLACEBO_COMPARATOR): - IV 0.9% sterile saline
- Intravenous Tranexamic Acid followed by Intravenous Placebo (Type: ACTIVE_COMPARATOR): * 1g TXA administered intravenous piggyback at start of surgery OR~* 1g TXA administered intravenous piggyback at start and at time of closure of surgery~* IV 0.9% sterile saline

Based on this trial design, predict the completion outcome and termination type (if applicable).